FOLH1 and prostate carcinoma: The expression levels of PSMA on C4‐2B, LNCaP, and PC3‐PIP prostate cancer cells were measured, using the PSMA‐targeting 111In‐DTPA‐SCN‐antibody, to be 126,000 ± 12,000, 210,000 ± 12,000, and 3,400,000 ± 78,000 copies per cell, respectively; the PSMA‐targeting antibody exhibited comparable KD across all cell lines (Table S1 and Figure S2).